Characterization of the designer benzodiazepine diclazepam and preliminary data on its metabolism and pharmacokinetics

Drug Testing and Analysis

Volumn 6, Issue 7-8, 2014, Pages 757-763

  Moosmann, Bjoern ^a,b   Bisel, Philippe ^b   Auwärter, Volker ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Benzodiazepines; Designer drugs; Diclazepam; LC MS MS; Metabolism

Indexed keywords

BODY FLUIDS; GAS CHROMATOGRAPHY; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; METABOLITES; NUCLEAR MAGNETIC RESONANCE; PHARMACOKINETICS; PHYSIOLOGY;

BENZODIAZEPINES; DESIGNER DRUGS; DETECTABILITY; DICLAZEPAM; IMMUNOCHEMICAL ASSAYS; LC-MS-MS; LC.MS/MS; LOWEST PRICE; ONLINE SHOPS; URINE SAMPLE;

METABOLISM;

BENZODIAZEPINE; CREATININE; DELORAZEPAM; DICLAZEPAM; DRUG METABOLITE; LORAZEPAM; LORMETAZEPAM; UNCLASSIFIED DRUG; 2-CHLORODIAZEPAM; BENZODIAZEPINE DERIVATIVE; DESIGNER DRUG; DIAZEPAM;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG STRUCTURE; HUMAN; HUMAN EXPERIMENT; IMMUNOCHEMISTRY; LIMIT OF DETECTION; LIQUID CHROMATOGRAPHY; MASS FRAGMENTOGRAPHY; NUCLEAR MAGNETIC RESONANCE; PRIORITY JOURNAL; SERUM; TANDEM MASS SPECTROMETRY; URINE; ANALOGS AND DERIVATIVES; METABOLISM; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY;

ADULT; BENZODIAZEPINES; CHROMATOGRAPHY, LIQUID; DESIGNER DRUGS; DIAZEPAM; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; TANDEM MASS SPECTROMETRY;

EID: 84904569385     PISSN: 19427603     EISSN: 19427611     Source Type: Journal    
DOI: 10.1002/dta.1628     Document Type: Article

References (17)

1. B. Moosmann, M. Hutter, L. Huppertz, S. Ferlaino, L. Redlingshöfer, V. Auwärter . Characterization of the designer benzodiazepine pyrazolam and its detectability in human serum and urine. Forensic Toxicol. 2013, 31, 263.
2. EMCDDA. Reporting form on the new drug Pyrazolam. REITOX, Finland, 2012.
3. B. Moosmann, L. Huppertz, M. Hutter, A. Buchwald, S. Ferlaino, V. Auwärter . Detection and identification of the designer benzodiazepine flubromazepam and preliminary data on its metabolism and pharmacokinetics. J. Mass Spectrom. 2013, 48, 1150.
4. L.H. Sternbach, R.I. Fryer, W. Metlesics, E. Reeder, G. Sach, G. Saucy, A. Stempel . Quinazolines and 1, 4-Benzodiazepines. VI.1a Halo-, Methyl-, and Methoxy-substituted 1, 3-Dihydro-5-phenyl-2H-1, 4-benzodiazepin-2-ones1b, c. J. Org. Chem. 1962, 27, 3788.
5. M. Babbini, M. Gaiardi, M. Bartoletti . Anxiolytic versus sedative properties in the benzodiazepines series: Differencies in structure - activity relationships. Life Sci. 1979, 25, 15.
6. L.H. Sternbach, L.O. Randall, R. Banziger, H. Lehr . Chapter 6: Structure-activity relationships in the 1, 3-benzodiazepine series, in Drugs Affecting the Central Nervous System, (Ed: A. Burger ), Edward Arnold, London, 1968.
7. E. Sigel, M.T. Schaerer, A. Buhr, R. Baur . The benzodiazepine binding pocket of recombinant α1ß2γ2 γ-Aminobutyric AcidA receptors: Relative orientation of ligands and amino acid side chains. Mol. Pharmacol. 1998, 54, 1097.
8. C.M. Bradley, A.N. Nicholson . Activity of the chloro- and triazolo-benzodiazepines: Behavioural studies in the monkey (Macaca mulatta). Neuropharmacology 1984, 23, 327.
9. UNODC. Recommended Methods for the Detection and Assay of Barbiturates and Benzodiazepines in Biological Specimens, manual for use by National laboratories. United Nations Office on Drugs and Crime, New York, 1997.
10. L.A. Berrueta, B. Gallo, F. Vicente . Biopharmacological data and high-performance liquid chromatographic analysis of 1, 4-benzodiazepines in biological fluids: A review. J. Pharmaceut. Biomed. 1992, 10, 109.
11. L.D. Bo, F. Marcucci, E. Mussini, D. Perbellini, A. Castellani, P. Fresia . Plasma levels of chlorodesmethyldiazepam in humans, Biopharm. Drug Disposition 1980, 1, 123.
12. T.H. Williams, G.J. Sasso, J.J. Ryan, M.A. Schwartz . Novel application of proton nuclear magnetic resonance spectroscopy in the identification of 2'-chloronordiazepam metabolites in the dog. J. Med. Chem. 1979, 22, 436.
13. F.T. Peters, M. Hartung, M. Herbold, G. Schmitt, T. Daldrup, F. Mußhoff . Anhang B zu den Richtlinien der GTFCh zur Qualitätssicherung bei forensisch-toxikologischen Untersuchungen; Anforderungen an die Validierung von Analysenmethoden. Toxichem. Krimtech. 2009, 76, 185.
14. Uniformity of content of single-dose preparations, European Pharmacopoeia, 8th edn. Council of Europe. Available at: http://online.edqm.eu/EN/entry.htm. [20 February 2014]
15. P. Griffiths, R. Sedefov, A.N.A. Gallegos, D. Lopez . How globalization and market innovation challenge how we think about and respond to drug use: 'Spice' a case study. Addiction 2010, 105, 951.
16. D.J. Greenblatt, R.T. Schillings, A.A. Kyriakopoulos, R.I. Shader, S.F. Sisenwine, J.A. Knowles, H.W. Ruelius . Clinical pharmacokinetics of lorazepam. I. Absorption and disposition of oral 14C-lorazepam. Clin. Pharmacol. Ther. 1976, 20, 329.
17. 14C. Eur. J. Drug Metab. Ph. 1979, 4, 237.